Banking Recap

Quanterix Corp Announces Acquisition

This transaction is a stock-for-stock merger in which Quanterix Corp (ticker QTRX), a healthcare sector company, is acquiring Akoya Biosciences, Inc. The deal is classified under the M&A product group, and the disclosed value is not stated in the source document.

Mar 28, 2025·SEC EDGAR (S-4)·pending regulatory·stock-for-stock merger

The facts in this briefing are sourced from an SEC EDGAR Form S-4 filed and published on March 28, 2025. The transaction's current status is pending regulatory review.

Only one financial advisor is named in the facts block: Goldman Sachs & Co. LLC served as financial advisor to the acquirer, Quanterix, in a lead capacity. The source sentence references consent language for Goldman Sachs & Co. LLC's opinion letter under the caption The Merger, Opinion of Quanterix's Financial Advisor, confirming the firm's role was specifically to render a fairness opinion to Quanterix in connection with the merger.

No legal advisors are identified in the facts block for either Akoya Biosciences or Quanterix.

Beyond confirming the transaction is structured as a stock-for-stock merger, the facts block does not specify the exchange ratio, the treatment of outstanding equity awards or convertible securities, or any other structural terms of the merger agreement.

Several material facts remain undisclosed. The transaction's dollar value is explicitly stated as not disclosed in the source document. No financial advisor is named for Akoya Biosciences, the target, and no legal advisors are named for either party. No expected closing date is given, and the specific stock exchange ratio is not disclosed.